Immune toxicity remains a diagnosis of exclusion, and multidisciplinary collaboration remains the cornerstone for early diagnosis and treatment.
Chemo Plus Immunotherapy Shows Promise for Advanced Bladder Cancer
The combination of nivolumab, gemcitabine and cisplatin produces significant pathologic response rates in patients with muscle-invasive bladder cancer (MIBC) in the neoadjuvant setting, according to new data from the phase II Bladder Cancer Signal Seeking Trial.